weekly_roundup

BioTechSign Daily Catalyst Roundup - November 10, 2026

Top BioTechSign catalyst names today: EYPT, PRAX, NKTR, NUVB, CAPR, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 10, 2026

Daily Biotech Catalyst Digest: November 10, 2026

EYPT leads the current BioTechSign screen at 84.2/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
EYPTEyePoint, Inc.84.2Aclinical activity 100%, short interest 70%, dilution risk 43%
PRAXPraxis Precision Medicine76.8Bclinical activity 100%, PDUFA timing 75%, short interest 50%
NKTRNektar Therapeutics74.4Bpublication signal 100%, short interest 90%, clinical activity 75%
NUVBNuvation Bio73.6Bclinical activity 88%, PDUFA timing 75%, short interest 70%
CAPRCapricor Therapeutics, Inc.70.3BPDUFA timing 100%, publication signal 100%, short interest 90%
BBIOBridgeBio Pharma69.1Bpublication signal 100%, clinical activity 100%, PDUFA timing 90%

Recent Grade-Change Queue

  • AMGN (Amgen Inc) currently grades D with a 39.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 75%, dilution risk 10%.
  • ARGX (argenx SE) currently grades F with a 17.4/100 catalyst score. Main inputs: publication signal 100%, dilution risk 15%, short interest 10%.
  • JAZZ (Jazz Pharmaceuticals plc) currently grades F with a 23.5/100 catalyst score. Main inputs: publication signal 100%, PDUFA timing 35%, short interest 30%.
  • RNAC (Cartesian Therapeutics, Inc.) currently grades D with a 43.8/100 catalyst score. Main inputs: publication signal 100%, short interest 50%, dilution risk 38%.
  • GRFS (Grifols SA) currently grades F with a 20.2/100 catalyst score. Main inputs: publication signal 100%, dilution risk 19%, short interest 10%.
  • RCKT (Rocket Pharmaceuticals) currently grades F with a 28.4/100 catalyst score. Main inputs: publication signal 100%, dilution risk 54%, short interest 50%.
  • RZLT (Rezolute, Inc.) currently grades D with a 37.5/100 catalyst score. Main inputs: short interest 70%, dilution risk 57%, clinical activity 50%.
  • IBRX (ImmunityBio, Inc.) currently grades C with a 62.5/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, PDUFA timing 75%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.